Table 1.

Comparison of the GDCN and TGNR cohorts

ParameterAll Patients with MN
GDCN
(n=412)TGNR
(n=487)P Valuea
Age at MN diagnosis (yr, mean ± SD)50.9±1647.5±15.80.001
Males, N (%)238 (57.8)317 (65.1)0.03
Race, N (%)<0.0001
 Caucasian266 (64.6)332 (77.6)
 African American82 (19.9)25 (5.8)
 other64 (15.5)71 (16.6)
History of smoking, N (%)b0.34
 never100 (42.2)131 (37.3)
 ex-smoker72 (30.4)105 (29.9)
 smoker at MN diagnosis65 (27.4)115 (32.8)
Laboratory values at MN diagnosis (mean ± SD)
 albumin (g/dl)2.5±0.82.7±0.70.0004
 eGFR (ml/min per 1.73 m2)70.6±37.875.3±29.80.001
 24-hour proteinuria (g)8.6±66.9±5.0<0.0001
Immunosuppressive treatment, N (%)
 glucocorticoids261 (63.4)207 (42.5)<0.0001
 cyclophosphamide/chlorambucil88 (21.4)85 (17.5)0.15
 cyclosporine26 (6.3)43 (8.8)0.17
 MMF, MTX, or AZA21 (5.1)15 (3.1)0.13
 rituximab3 (0.7)
 any immunosuppressive therapy269 (65.3)247 (50.7)<0.0001
Patients with VTE
GDCN
(n=29)TGNR
(n=38)P Valuea
History of smoking, N (%)c1.00
 never5 (29.4)8 (28.6)
 ex-smoker5 (29.4)8 (28.6)
 smoker7 (41.2)12 (42.9)
Laboratory values at MN diagnosisd (mean ± SD)
 serum albumin (g/dl)2.2±0.52.25±0.60.52
 eGFR (ml/min per 1.73 m2)69±31.374.0±26.00.23
 24-hour proteinuria (g)9.9±5.07.1±4.90.02
Immunosuppressive treatment, N (%)
 glucocorticoids24 (82.8)21 (55.3)0.02
 Cytoxan/chlorambucil9 (31.0)13 (34.2)1.00
 cyclosporine5 (17.2)4 (10.5)0.49
 MMF, MTX, or AZA1 (3.4)3 (7.9)0.63
 rituximab0 (0)
 any immunosuppressive therapy24 (82.8)26 (68.4)0.26
  • GDCN, Glomerular Disease Collaborative Network; TGNR, Toronto Glomerulonephritis Registry; MN, membranous nephropathy; eGFR, estimated GFR; MMF, mycophenolate mofetil; MTX, methotrexate; AZA, azathioprine; VTE, venous thromboembolic event.

  • a P value was calculated by Fisher’s exact test for categorical variables and Wilcoxon two-samples test for continuous variables.

  • b Information was available in 237 and 350 patients, respectively.

  • c Laboratory values from the time of diagnostic biopsy for the overall cohort and at the time of first VTE for thrombotic patients.

  • d Information was available in 17 and 26 patients, respectively.